The Biopharma Industry Has a Data Integrity Problem
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward... Read More
Your Edge In Biotech.
About Alex Harding
Alex Harding is an internal medicine physician at Massachusetts General Hospital who sees patients in an urgent care clinic. He is also an associate at Atlas Venture, a biotechnology venture capital firm in Cambridge, MA. Alex completed his residency in internal medicine at Massachusetts General Hospital. He received an MD from Johns Hopkins School of Medicine and was selected for the Alpha Omega Alpha medical honors society. He was given the W. Barry Wood Student Research Award for his research describing a novel water purification process using naturally-occurring psoralens in limes to kill pathogenic organisms in drinking water. He graduated from Harvard Business School with an MBA and was a summer associate at SR One, a corporate life sciences venture capital firm. Alex founded a non-profit company called Water Ecuador, which provided clean and affordable drinking water to thousands of people in a low-income, rural region in Ecuador. He speaks Spanish fluently. Outside of work, he enjoys rugby and exploring around Boston with his wife and son.
The author’s views do not necessarily represent the views of his employer.
Latest Contributions
Nimble Pharmas and Plodding Biotechs: Responses to the IRA Have Flipped the Script
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward... Read More
Biopharma Has a Primary Care Problem
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward... Read More
The “D” Word: Delivery is the Next Frontier for Genetic Medicines
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward... Read More
Why Is It So Hard to Get Patients the Medicines They Need?
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward... Read More
Inflation Reduction Act: Big Changes Lurking for Drug Development
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward... Read More
Seek Truth and Kill Quickly: Learning the Hard Way About Biotech Startups
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward... Read More
Lessons from the Road: What I Learned from Remix’s Series B
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward... Read More